"Let food be your medicine, and let medicine be your food" Hippocrates (^^ - 500BC)
|
Nutri Pharma ASAKronprinsesse Marthas
Plass 1 P.O Box 1477, Vika N-0116 Oslo Norway Telephone +47 23 01 09 60 Telefax +47 23 01 09 70 Send e-mail |
Henrik Lund MD Ph.D Named as New CEOHenrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
Two-Thirds Respond to "Re-vaccination "Two-Thirds of Study Volunteers Respond to First-Ever "Re-vaccination " of Vacc-4x, Bionor Pharma's Peptide-based Therapeutic
HIV-Vaccine
Independent research report on Bionor published in Thomson Reuters' "Current Opinion in Investigational Drugs"To view the research report in its entirety, please follow the link.
Bill Clinton Was Right About Wasted HIV/AIDS Funding."In too many countries too much money goes to pay for too many people to go to too many meetings, get on too many airplanes,"
proclaimed the former U.S. President Bill Clinton in a keynote address at one of those very meetings, the XVIII Annual International
AIDS Conference which was held last week in Vienna..
International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV.New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic
vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS.
AIDS Will Be Conquered.Through its six days of presentations for 19,000 attendees, hundreds of seminars and more than 4,000 scientific 'posters'
examining every aspect of AIDS, the single message that stands out from the XVIII International AIDS Conference, which ended
in Vienna last week, is the cumulative progress on every front -- prevention, treatment, basic science and human rights..
BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIVNew data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic
vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS.
Results of Vac-4x HIV vaccine announced.Researchers with the Oslo University and Bionor Immuno at the XVIII International AIDS Conference in Vienna, Austria, recently
released the results of a re-vaccination study of Norway’s largest hospital using the company's furthest advance HIV vaccine
candidate, Vac-4x..
Reuters: Many forks loom in road to AIDS vaccine(Reuters) - AIDS experts and advocates gathering in Vienna this weekend for a conference on the pandemic will hear about progress
in protecting people from the deadly virus using drugs, and ways to affect behavior...
Financial Times: HIV / Aids: Discordant visions.Changing outlook: demonstrators in Cape Town last year raise fears about finance for action to combat the virus. But in contrast
to past wariness, South Africa sent its vice-president and minister of health to tell this week’s Vienna conference of a redoubled
prevention, testing and treatment effort. The country has one of the highest HIV burdens..
"Next Generation" HIV/AIDS Treatments Featured in NAPWA and The AIDS Institute's Community Forum at XVIII International AIDS ConferenceFour Therapeutic Vaccines Show Efficacy; Other Leading Therapeutic HIV Vaccines, Anti-Immune Hyperactivation, and Immune-Based
Therapies Hit Milestones..
Bionor presents at the XVIII International AIDS ConferenceBionor Immuno's Therapeutic HIV Vaccine Candidate Vacc-4x Targeting Conserved Domains of HIV Produce Immune Response Seven
Years after Inoculation
Changed Financial Calendar 2010(Oslo, 8 July 2010) The new Board of Directors of Bionor Pharma ASA has rescheduled the date for publishing of results for 2nd quarter 2010 from August 31 to August 30. The new financial calendar of 2010 is as follows: Feb 24, 2010 Results 4th quarter 2009 May 19, 2010 Annual General Meeting May 20, 2010 Results 1st quarter 2010 Aug 30, 2010 Results 2nd quarter 2010 Nov 18, 2010 Results 3rd quarter 2010 Feb 18, 2011 Results 4th quarter 2010
Mandatory notification of tradeThe Board Member of Bionor Pharma ASA, Thomas Falck, has today purchased 75,000 BIONOR shares..
Mandatory notification of tradeThe Chairman of the Board of Bionor Pharma ASA, Wenche Rolfsen, has today purchased 68,500 BIONOR shares..
Bionor Immuno Researchers Discover Pathway that Allows HIV “Natural Viral Suppressors” to Live Without Symptoms; Study Findings Confirm Potential for Vacc-C5A study performed in collaboration with the University of Maryland School of Medicine’s Institute for Human Virology leads
Bionor Immuno researchers to believe they have found a way to replicate the immune responses previously associated with “natural
viral suppressors,” those people who are able naturally to control HIV without medication, the Company announced today........
Bionor Pharma's re-vaccination study accepted as a poster at the XVIII International AIDS conferenceBionor Pharma's subsidiary, Bionor Immuno AS recently carried out a
re-vaccination study at Norway's largest hospital, using Vacc-4x, the company's
most advanced HIV-vaccine candidate...
Mandatory notification of tradeWenche Rolfsen, Chairman of the Board of Bionor Pharma ASA, has today acquired 65 000 shares in the Company
New name and new ticker from Monday 14.06.2010Nutri Pharma ASA changes the company's name to Bionor
Pharma ASA.
Nutri Pharma ASA to change name to Bionor Pharma ASAOn 19 May 2010 Nutri Pharma ASA's Annual General Meeting resolved to change the company name from Nutri Pharma ASA to Bionor
Pharma ASA.
Researchers Find that Investigational Therapeutic HIV Vaccine, Vacc-4x, is still effective (Produces Immune Response) in HIV Study Volunteers Seven Years After Injection31.05.2010 - Bionor Pharma’s subsidiary, Bionor Immuno AS completed a re-vaccination study at Norway’s largest hospital with
Vacc-4x, the company’s most advanced HIV-vaccine candidate.....
NutriPharma ASA and subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting27.05.2010 - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company
Nutri Pharma ASA will now be known as Bionor Pharma ASA.......
First Quarter Results 2010 Nutri Pharma ASA19.05.2010 - Please find attached financial statement for the 1st quarter of 2010.
Minutes from the Annual General Meeting of Nutri Pharma ASA19.05.2010 - Nutri Pharma ASA´s Annual General Meeting was held today, 19 May 2010. All proposed resolutions in the notice
to the meeting were approved by the shareholders....
The proposal of the Nomination Committee and amendment to item 11 of the Norwegian AGM summons14.05.2010 - The Nomination Committee proposes that the following candidates be elected to the Board of Directors of
Nutri Pharma ASA...
Ny CFO i Nutri Pharma ASA06.05.2010 - Rolf Henning Lem er ansatt som ny CFO i Nutri Pharma ASA. Rolf Henning skal, i tillegg til de funksjoner som
ligger under CFO-stillingen, bistå aktivt i arbeidet med å kommersialisere Bionor Immunos teknologiske plattform mot
farmasiselskaper internasjonalt....
Annual accounts 2009 approved by the Board of Directors28.04.2010 - The Board of Directors of Nutri Pharma ASA has today approved the Annual Accounts for 2009...
Invitation to the Annual General Meeting28.04.2010 - The Annual General Meeting of Nutri Pharma ASA will be held on Wednesday 19 May 2010, 10:00 a.m. at the company's
offices at Kronprinsesse Märthas plass 1...
Minutes from the EGM28.04.2010 - The Extraordinary General Meeting of Nutri Pharma ASA has today resolved to elect Mr. Eric Cameron as
Chairman of the Board of Directors....
Extraordinary shareholders meeting07.04.2010 - Nutri Pharma ASA has today sent the attached notice to shareholders of the company...
Changed Financial Calendar 201006.04.2010 - Reference is made to the notification from the company of 6 April 2010. Due to changes in the Board of Directory
of Nutri Pharma ASA there is need for an
Extraordinary General Meeting the 28th of April...
Innkalling til Ekstraordinær Generalforsamling05.04.2010 - Det innkalles herved til ekstraordinær generalforsamling i Nutri Pharma ASA den 28.april 2010 klokken 10.00 på
selskapets forretningskontor i Kronprinsesse Märtas Plass 1 i Oslo...
Mandatory notification of trade - Nutri Pharma ASA05.04.2010 - Reference is made to the primary insider notification of 18 February 2010 regarding Lars Høie and notification
from the company of 6 April 2010. Lars Høie
is a member of the Board of Directors of Nutri Pharma ASA...
CHANGES TO THE BOARD OF DIRECTORS OF NUTRI PHARMA ASA05.04.2010 - Thorleif Krarup, chairman of the board of directors of Nutri Pharma ASA (ticker "NUT") has informed that he wishes
to resign from his position as chairman of
the board....
New path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers16.03.2010 - Vacc-C5 to Move from Lab to Phase I/II Clinical Trial. Based on encouraging results from pre-clinical research,
Bionor Immuno AS, today announced intentions to take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5
into a Phase I/II clinical trial....
Subsequent Offering17.03.2010 - Reference is made to stock exchange notice dated 8 March 2010, the prospectus dated 18 February 2010 regarding
the subsequent offering of up to 10,000,000
Subsequent Offering Shares in Nutri Pharma ASA ("Nutri Pharma") to a price of NOK 2.00 per share...
Vacc-C5 to be prepared for phase I/II clinical trial15.03.2010 - Based on encouraging results from pre-clinical research, Nutri Pharma ASA's wholly owned subsidiary Bionor Immuno
AS, has today announced that it will take
the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 towards phase I/II clinical trial...
Completion of Subsequent Offering08.03.2010 - Reference is made to the prospectus dated 18 February 2010 regarding the subsequent offering of up
to 10,000,000 Subsequent Offering Shares in Nutri Pharma ASA ("Nutri Pharma") to a price of NOK 2.00 per share, constituting
gross proceeds of up to NOK 20,000,000 (the "Subsequent Offering")....
Changed Financial Calendar 201005.03.2010 - Due to changed plan for Board Meetings in Nutri Pharma ASA the release of Q2 for 2010 is postponed from 26(th)
of August, to 31(st) of August 2010....
Approved supplemental prospectus26.02.2010 - Oslo Børs has approved following supplemental
prospectus:
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
Supplemental prospectus
CORRECTION: FOURTH QUARTER AND PRELIMINARY 2009 RESULTS23.02.2010 - This is a correction of the announcement from 19:02 23.02.2010 CET. Reason for the correction: The attached file
appeared in zip-format for some receipients. Please see the Q4 report in a pdf-format instead....
FOURTH QUARTER AND PRELIMINARY 2009 RESULTS23.02.2010 - Turnover from sale to Nikken was for FY 2009 MNOK 14.1. Nikken topped up its inventories in conjunction with
the launch in May 2009...
Mandatory notification of trade22.01.2010 - KAG AS a company fully owned and controlled by Birger Sørensen CEO of Bionor Immuno AS (a subsidiary of Nutri
Pharma ASA), has has today purchased 90.000 NUT
shares at NOK 2.10 per share....
New Primary insiders in NUT 19 February 201019.02.2010 - Reference is made to the stock exchange notification published by 18 February 2010 regarding primary insiders
in Nutri Pharma ASA ("NUT")....
Approved prospectus19.02.2010 - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. Please
visit this link to access the prospectus.....
Commencement of subscription period for subsequent offering19.02.2010 - Reference is made to stock exchange notice 18
February 2010 regarding completion of private placement in Nutri Pharma ASA ("NUT" or the "Company") of 50 million shares
(the "Private Placement") as well as previous stock exchange notices....
Approved prospectus18.02.2010 - Offering and listing of up to 10,000,000 Subsequent Offering Shares each with a nominal value of NOK 0.25 in
connection with a repair offering to
Eligible Shareholders at a subscription price of NOK
2.00 raising total gross proceeds of up to NOK
20,000,000...
Share capital increase and registrations in the Norwegian Register of Business Enterprises18.02.2010 - Reference is made to the stock exchange notice of 12 February 2010 regarding the extraordinary general
meeting of Nutri Pharma ASA (the "Company"),.....
|
2006 Nutri Pharma ASA Telephone +47 23 01 09 60 Telefax +47 23 01 09 70
Contact Page
